Recent rapid biotechnological breakthroughs have led to the identification of complex and
unique molecular features that drive malignancies. Precision medicine has exploited next …

Abstract Endometrial cancer accounts for~ 76,000 deaths among women each year
worldwide. Disease mortality and the increasing number of new diagnoses make …

Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome-
and immune-targeted drugs that have transformed the outcomes of some malignancies …

Precision medicine focuses on DNA abnormalities, but not all tumors have tractable
genomic alterations. The WINTHER trial (NCT01856296) navigated patients to therapy on …

Widespread clinical laboratory implementation of next-generation sequencing–based
cancer testing has highlighted the importance and potential benefits of standardizing the …

High-throughput genomic analyses may improve outcomes in patients with advanced
cancers. MOSCATO 01 is a prospective clinical trial evaluating the clinical benefit of this …

Background Molecularly targeted agents have been reported to have anti-tumour activity for
patients whose tumours harbour the matching molecular alteration. These results have led …

Over the past 15 years, rapid progress has been made in developmental therapeutics,
especially regarding the use of matched targeted therapies against specific oncogenic …

Since June 2019, under the umbrella of the national health insurance system, Japan has
started cancer genomic medicine (CGM) with comprehensive genomic profiling (CGP) tests …

After cardiovascular disease, cancer is the leading cause of death worldwide with
devastating health and economic consequences, particularly in developing countries. Inter …